Australia - engleză - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - cefaclor monohydrate, quantity: 393.4 mg (equivalent: cefaclor, qty 375 mg) - tablet, modified release - excipient ingredients: mannitol; hypromellose; hyprolose; methacrylic acid copolymer; stearic acid; magnesium stearate; propylene glycol; purified talc; colour - indications as 7 august 1996: ceclor cd is indicated for the treatment of the following types of infections caused by susceptible organisms, in adults and children aged 12years or older: acute bronchitis and acute exacerbations of chronic bronchitis; upper respiratory infections, including phryngitis, tonsillitis and acute bacterial sinusitis; community-acquired pneumonia of mild to moderate severity (excluding atypical pneumonia); symptomatic lower urinary tact infections, including cystitis; skin and skin structure infections. note: 1. penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. ceclor cd is generally effective in the eradication of streptococci from the oropharynx; however, substantial data establishing the efficacy of ceclor cd in the subsequent prevention of rheumatic fever are not available. 2. bacteriological studies to determine the causative organism and its susceptibility to cefaclor should be performed. therapy may be started while awaiting the results of these studies. once these results become available, antimicrobial therapy should be adjusted accordingly.

Australia - engleză - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - cefaclor monohydrate, quantity: 26.86 mg/ml (equivalent: cefaclor, qty 25 mg/ml) - oral liquid, powder for - excipient ingredients: methylcellulose; sodium lauryl sulfate; dimeticone 350; xanthan gum; tapioca starch; erythrosine; sucrose; flavour - ceclor is indicated for the treatment of the following types of infections caused by or likely to be caused by susceptible organisms: lower respiratory infections, including pneumonia, bronchitis and exacerbations of chronic bronchitis. upper respiratory tract infections, including pharyngitis, tonsillitis and otitis media. skin and skin structure infections. urinary tract infections including pyelonephritis and cystitis. note: 1. penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. ceclor appears to be as effective as phenoxymethyl penicillin in the eradication of streptococci from the nasopharynx; however, substantial data establishing the efficacy of ceclor in the subsequent prevention of rheumatic fever are not available at present. 2. appropriate culture and susceptibility studies should be performed to determine susceptibility of the causative organism to cefaclor.

Australia - engleză - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - cefaclor monohydrate, quantity: 53.72 mg/ml (equivalent: cefaclor, qty 50 mg/ml) - oral liquid, powder for - excipient ingredients: methylcellulose; sodium lauryl sulfate; dimeticone 350; xanthan gum; tapioca starch; erythrosine; sucrose; flavour - ceclor is indicated for the treatment of the following types of infections caused by or likely to be caused by susceptible organisms: lower respiratory infections, including pneumonia, bronchitis and exacerbations of chronic bronchitis. upper respiratory tract infections, including pharyngitis, tonsillitis and otitis media. skin and skin structure infections. urinary tract infections including pyelonephritis and cystitis. note: 1. penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. ceclor appears to be as effective as phenoxymethyl penicillin in the eradication of streptococci from the nasopharynx; however, substantial data establishing the efficacy of ceclor in the subsequent prevention of rheumatic fever are not available at present. 2. appropriate culture and susceptibility studies should be performed to determine susceptibility of the causative organism to cefaclor.

Australia - engleză - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - cefaclor monohydrate, quantity: 26.22 mg/ml (equivalent: cefaclor, qty 25 mg/ml) - oral liquid, powder for - excipient ingredients: methylcellulose; sodium lauryl sulfate; dimeticone 350; xanthan gum; erythrosine; sucrose; pregelatinised starch; flavour - ceclor is indicated for the treatment of the following types of infections caused by or likely to be caused by susceptible organisms: lower respiratory infections, including pneumonia, bronchitis and exacerbations of chronic bronchitis. upper respiratory tract infections, including pharyngitis, tonsillitis and otitis media. skin and skin structure infections. urinary tract infections including pyelonephritis and cystitis. note: 1. penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. ceclor appears to be as effective as phenoxymethyl penicillin in the eradication of streptococci from the nasopharynx; however, substantial data establishing the efficacy of ceclor in the subsequent prevention of rheumatic fever are not available at present. 2. appropriate culture and susceptibility studies should be performed to determine susceptibility of the causative organism to cefaclor.

Australia - engleză - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - cefaclor monohydrate, quantity: 52.45 mg/ml (equivalent: cefaclor, qty 50 mg/ml) - oral liquid, powder for - excipient ingredients: methylcellulose; sodium lauryl sulfate; dimeticone 350; xanthan gum; erythrosine; sucrose; pregelatinised starch; flavour - ceclor is indicated for the treatment of the following types of infections caused by or likely to be caused by susceptible organisms: lower respiratory infections, including pneumonia, bronchitis and exacerbations of chronic bronchitis. upper respiratory tract infections, including pharyngitis, tonsillitis and otitis media. skin and skin structure infections. urinary tract infections including pyelonephritis and cystitis. note: 1. penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. ceclor appears to be as effective as phenoxymethyl penicillin in the eradication of streptococci from the nasopharynx; however, substantial data establishing the efficacy of ceclor in the subsequent prevention of rheumatic fever are not available at present. 2. appropriate culture and susceptibility studies should be performed to determine susceptibility of the causative organism to cefaclor.

Australia - engleză - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - cefaclor monohydrate, quantity: 393.36 mg (equivalent: cefaclor, qty 375 mg) - tablet, modified release - excipient ingredients: hypromellose; colloidal anhydrous silica; hyprolose; lactose monohydrate; purified talc; magnesium stearate; titanium dioxide; macrogol 400; indigo carmine aluminium lake; propylene glycol; purified water; isopropyl alcohol; iron oxide black - for the treatment of the following infections caused by susceptible organisms, in adults and children 12 years and older: lower respiratory infections, including community acquired pneumonia of mild to moderate severity (excluding atypical pneumonia), acute bronchitis and exacerbation of chronic bronchitis. upper respiratory infections, including pharyngitis, tonsillitis and acute bacterial sinusitis. symptomatic lower urinary tract infections, including cystitis. skin and skin structure infections.

Australia - engleză - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - cefaclor monohydrate, quantity: 393.36 mg (equivalent: cefaclor, qty 375 mg) - tablet, modified release - excipient ingredients: lactose monohydrate; colloidal anhydrous silica; purified talc; hyprolose; hypromellose; magnesium stearate; propylene glycol; purified water; isopropyl alcohol; iron oxide black; titanium dioxide; macrogol 400; indigo carmine aluminium lake - for the treatment of the following infections caused by susceptible organisms, in adults and children 12 years and older: lower respiratory infections, including community acquired pneumonia of mild to moderate severity (excluding atypical pneumonia), acute bronchitis and exacerbation of chronic bronchitis. upper respiratory infections, including pharyngitis, tonsillitis and acute bacterial sinusitis. symptomatic lower urinary tract infections, including cystitis. skin and skin structure infections.

Iordania - engleză - JFDA (Jordan Food & Drug Administration - المؤسسة العامة للغذاء والدواء)

شركة الشرق الاوسط للصناعات الدوائية - middle east pharmaceutical and chemical industries - cefaclor (as monohydrate)250 mg - (as monohydrate)250 mg

Iordania - engleză - JFDA (Jordan Food & Drug Administration - المؤسسة العامة للغذاء والدواء)

شركة الشرق الاوسط للصناعات الدوائية - middle east pharmaceutical and chemical industries - cefaclor as monohydrate 500 mg - as monohydrate 500 mg

Iordania - engleză - JFDA (Jordan Food & Drug Administration - المؤسسة العامة للغذاء والدواء)

شركة الشرق الاوسط للصناعات الدوائية - middle east pharmaceutical and chemical industries - cefaclor (as monohydrate) 250 mg - (as monohydrate) 250 mg